Polynovo Limited (AU:PNV) has released an update.
PolyNovo Limited has reported a significant increase in their FY24 unaudited financial results, with total revenue soaring to A$104.8m, marking a 57.5% rise from the previous year. The growth was led by a robust 49% increase in U.S. sales and a 73.1% jump in sales in the rest of the world, indicating strong global demand for their NovoSorb technology in complex wound management. The company also highlighted its impact in conflict zones and developing countries, with over 50,000 patients treated worldwide.
For further insights into AU:PNV stock, check out TipRanks’ Stock Analysis page.
